PathAI logo

PathAI Announces Research Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting

The four research posters demonstrate the efficacy and utility of AI-powered digital pathology for reducing variability in histologic scoring and quantitatively characterizing disease severity in tissue samples from individuals with metabolic dysfunction-associated steatohepatitis.

 Boston, MA – November 10, 2023 PathAI, a leading technology company which combines AI-powered pathology solutions and algorithm deployment expertise with end-to-end central pathology and histology services, today announced it will present research on advances in AI-based approaches through four poster presentations at the American Association for the Study of Liver Diseases Conference on November 10-14 in Boston, Massachusetts. The posters showcase PathAI’s ongoing commitment to cutting-edge research that advances the understanding and treatment of NASH/MASH using AI-powered digital pathology.
Machine learning-assisted fibrosis staging in H&E-stained tissue is comparable to staging with Masson’s Trichrome in non-alcoholic steatohepatitis (poster 2070-A)

In this research, PathAI demonstrated the utility of its novel, proprietary AI-powered digital pathology product called NASH ExploreTM to detect collagen and fibrosis signals from H&E-stained whole slide images, and enable liver pathologists to accurately stage fibrosis from these H&E images. Furthermore, the co-authors demonstrated that leveraging the AI-derived fibrosis heatmap overlays over H&E whole slide images for fibrosis staging reduced inter-pathologist staging variability relative to staging performed via Masson’s Trichrome. These results motivate further investigation into the potential to reduce the need for Masson’s Trichrome staining in NASH/MASH clinical trial workflows.

This work will be presented on Saturday, November 11 from 1:00-2:00 p.m. E.T.
AI-based cellular-level characterization of tissue microarchitecture in non-alcoholic steatohepatitis (poster 2006-A)

NASH Explore is an AI-powered digital pathology tool that enables automated detection, visualization, and zonated quantification of 14 categories of tissue regions and over 10 cell types, producing a panel of >1000 quantitative Human-Interpretable histologic Features (HIFs) from H&E whole slide images of liver biopsy tissue. In this collaborative research project, the co-authors demonstrate the biological validity of the quantitative histologic features generated by NASH Explore.

This work will be presented on Saturday, November 11 from 1:00-2:00 p.m. E.T.
Artificial intelligence-based measurement of non-alcoholic steatohepatitis (AIM-NASH) improves individual pathologists accuracy and decreases inter-pathologist variability in NASH assessment (poster 2010-A)

In this study, Artificial Intelligence-based Measurement of Non-Alcoholic Steatohepatitis (AIM-NASH) algorithm was evaluated for accuracy alone and for use as an assistive tool to pathologists in assessment of liver biopsies in a NASH clinical trial population. This research demonstrates that AIM-NASHTM may help to standardize histologic scoring for NASH by increasing accuracy for lobular inflammation and ballooning, the features most difficult to score in clinical trial populations. Use of AI-assist AIM-NASH also increased agreement between pathologists for all features.

This work will be presented on Saturday, November 11 from 8:00-9:00 a.m. E.T.
Artificial intelligence-based measurement of NASH Histology (AIM-NASH) recapitulates primary results from Phase 3 study of resmetirom for treatment of NASH/MASH (Abstract #48735)

AIM-NASH is an AI-powered digital pathology tool that accurately and reproducibly performs NASH CRN scoring of steatosis, ballooning, lobular inflammation, and fibrosis from whole slide images of H&E- and Masson’s Trichrome-stained liver biopsy tissue. In this collaborative research project, the co-authors demonstrate that all primary histologic endpoints that were met by the central pathologists in a Phase 3 study of resmetirom for treatment of NASH/MASH were also met with statistical significance by AIM-NASH, with clear detection of a dose-response. This adds to the existing body of evidence suggesting that AIM-NASH detects true drug effect, while also offering highly repeatable and reproducible histologic scoring.

This work will be presented on Monday, November 13 from 1:00-2:00 p.m. E.T.

Please visit the PathAI booth, D3100, to learn more and meet the team.
About PathAI

PathAI is a recognized leader in the biopharma partnering space, uniquely combining AI-powered pathology solutions with end-to-end central pathology and histology services. The company supports biopharma partners in executing clinical trials where pathology-based endpoints, biomarker classification, and/or superior histology quality are critical to successfully gauging therapeutic efficacy, accelerating drug development for complex diseases. PathAI has already supported multiple Phase 2 clinical trials in NASH, IBD, and breast cancer, as well as oncology neoadjuvant trials, and is now expanding into larger scale global Phase 3 studies, as well as additional indications.

PathAI provides a fully integrated approach to clinical trials, enabling pharma partners to leverage the power of AI without the heavy lift of implementation. This helps reduce the impact of challenges associated with clinical trials, including unreliable turnaround times, variable histology, stain or scan/digitization quality, and challenging assessment of histological endpoints. The lab offers all major immunohistochemistry staining platforms, with flexible workflows across different scanners, stains, and biopsy types, which improves the quality of clinical trials. Services include access to PathAI’s extensive network of over 500 US Board Certified pathologists to perform high quality reading with rapid turnaround time in a cost-effective manner, plus seamless integration of PathAI's advanced AI-solutions to ensure high-quality, reproducible results with every scan.

PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified diagnostics clinical laboratory (formerly known as Poplar Healthcare) – one of the country’s largest anatomic pathology labs – in Memphis, TN. For more information, please visit


AIM-NASH & NASH Explore are For Research Use Only. Not for use in diagnostic procedures

Get In Touch

For media inquiries, please contact [email protected]
Path AI seating area overlooking Fenway Park in Boston